SG11201903344XA - Non-human animals having an engineered immunoglobulin lambda light chain locus - Google Patents
Non-human animals having an engineered immunoglobulin lambda light chain locusInfo
- Publication number
- SG11201903344XA SG11201903344XA SG11201903344XA SG11201903344XA SG11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA
- Authority
- SG
- Singapore
- Prior art keywords
- rover
- road
- tarrytown
- saw mill
- human
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000005260 human cell Anatomy 0.000 abstract 2
- 241001061260 Emmelichthys struhsakeri Species 0.000 abstract 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662417845P | 2016-11-04 | 2016-11-04 | |
US201762567932P | 2017-10-04 | 2017-10-04 | |
PCT/US2017/060006 WO2018128691A1 (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903344XA true SG11201903344XA (en) | 2019-05-30 |
Family
ID=62025924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903344XA SG11201903344XA (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
SG10201913483XA SG10201913483XA (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913483XA SG10201913483XA (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
Country Status (24)
Country | Link |
---|---|
US (2) | US10820582B2 (el) |
EP (3) | EP3407709B9 (el) |
JP (4) | JP6884860B2 (el) |
KR (4) | KR102658529B1 (el) |
CN (2) | CN109996441B (el) |
AU (2) | AU2017391167B2 (el) |
BR (1) | BR112019008675A2 (el) |
CA (1) | CA3038720A1 (el) |
CY (1) | CY1123491T1 (el) |
DK (2) | DK3766343T3 (el) |
ES (2) | ES2915609T3 (el) |
HR (2) | HRP20220888T1 (el) |
HU (2) | HUE061980T2 (el) |
IL (2) | IL308197A (el) |
LT (2) | LT3407709T (el) |
MA (2) | MA44091A (el) |
MX (2) | MX2019005256A (el) |
PL (2) | PL3766343T3 (el) |
PT (2) | PT3766343T (el) |
RS (2) | RS60886B1 (el) |
RU (2) | RU2757665C2 (el) |
SG (2) | SG11201903344XA (el) |
SI (2) | SI3766343T1 (el) |
WO (1) | WO2018128691A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2753774T3 (es) * | 2012-02-01 | 2020-04-14 | Regeneron Pharma | Ratones humanizados que expresan cadenas pesadas que contienen dominios VL |
EP3384030A4 (en) | 2015-12-03 | 2019-07-03 | Trianni, Inc. | IMPROVED IMMUNOGLULINIVITY |
DK3766343T3 (da) | 2016-11-04 | 2022-06-20 | Regeneron Pharma | Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus |
WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
AU2019242586A1 (en) | 2018-03-26 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
SI3629720T1 (sl) | 2018-06-14 | 2022-04-29 | Regeneron Pharmaceuticals, Inc. | Nehumane živali zmožne prerazporeditve DH-DH v kodirnih zaporedjih težke verige imunoglobulina |
CN113473850A (zh) | 2019-02-22 | 2021-10-01 | 瑞泽恩制药公司 | 具有遗传修饰的钠通道的啮齿动物及其使用方法 |
KR20220025839A (ko) * | 2019-07-01 | 2022-03-03 | 트리아니, 인코포레이티드 | 유전자이식 포유동물 및 이의 사용 방법 |
EP4211155A1 (en) | 2020-09-11 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
EP4262373A1 (en) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
BR112023011689A2 (pt) | 2020-12-23 | 2023-10-31 | Regeneron Pharma | Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero |
US20220195014A1 (en) | 2020-12-23 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
WO2005007696A2 (en) * | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
AU2009329365B2 (en) * | 2008-12-18 | 2016-01-14 | Roger Kingdon Craig | Non-human transgenic animals expressing humanised antibodies and use thereof |
US20120204278A1 (en) * | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
HUE055817T2 (hu) * | 2009-07-08 | 2021-12-28 | Kymab Ltd | Állatmodellek és terápiás molekulák |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
IL300712A (en) | 2010-06-22 | 2023-04-01 | Regeneron Pharma | Mice with light chain to human |
PL2550363T3 (pl) | 2011-02-25 | 2015-05-29 | Regeneron Pharma | Myszy adam6 |
EP3216871B1 (en) | 2011-10-17 | 2021-12-22 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
PT2793567T (pt) * | 2011-12-20 | 2019-05-27 | Regeneron Pharma | Murganhos de cadeia leve humanizada |
RU2690352C2 (ru) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Генетическая модификация крыс |
DK2840892T3 (en) * | 2013-02-20 | 2018-07-23 | Regeneron Pharma | Non-human animals with modified heavy chain immunoglobulin sequences |
US9788534B2 (en) * | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
TW201546284A (zh) * | 2013-10-01 | 2015-12-16 | Kymab Ltd | 動物模式及治療分子 |
RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
PL3152312T3 (pl) | 2014-06-06 | 2020-08-10 | Regeneron Pharmaceuticals, Inc. | Sposoby i kompozycje do modyfikowania docelowego locus |
PT3155099T (pt) | 2014-06-23 | 2018-04-20 | Regeneron Pharma | Montagem de dna mediada por nuclease |
KR102531016B1 (ko) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
RU2707137C2 (ru) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания |
DK3766343T3 (da) | 2016-11-04 | 2022-06-20 | Regeneron Pharma | Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus |
-
2017
- 2017-11-03 DK DK20180508.2T patent/DK3766343T3/da active
- 2017-11-03 CN CN201780067880.6A patent/CN109996441B/zh active Active
- 2017-11-03 WO PCT/US2017/060006 patent/WO2018128691A1/en active Application Filing
- 2017-11-03 LT LTEP17863293.1T patent/LT3407709T/lt unknown
- 2017-11-03 MA MA044091A patent/MA44091A/fr unknown
- 2017-11-03 BR BR112019008675A patent/BR112019008675A2/pt unknown
- 2017-11-03 EP EP17863293.1A patent/EP3407709B9/en active Active
- 2017-11-03 SI SI201731147T patent/SI3766343T1/sl unknown
- 2017-11-03 PT PT201805082T patent/PT3766343T/pt unknown
- 2017-11-03 JP JP2019522647A patent/JP6884860B2/ja active Active
- 2017-11-03 SG SG11201903344XA patent/SG11201903344XA/en unknown
- 2017-11-03 KR KR1020237002504A patent/KR102658529B1/ko active IP Right Grant
- 2017-11-03 IL IL308197A patent/IL308197A/en unknown
- 2017-11-03 HU HUE20180508A patent/HUE061980T2/hu unknown
- 2017-11-03 RS RS20201205A patent/RS60886B1/sr unknown
- 2017-11-03 KR KR1020197015717A patent/KR102319069B1/ko active IP Right Grant
- 2017-11-03 SG SG10201913483XA patent/SG10201913483XA/en unknown
- 2017-11-03 LT LTEP20180508.2T patent/LT3766343T/lt unknown
- 2017-11-03 EP EP22164751.4A patent/EP4082334A1/en active Pending
- 2017-11-03 AU AU2017391167A patent/AU2017391167B2/en active Active
- 2017-11-03 PT PT178632931T patent/PT3407709T/pt unknown
- 2017-11-03 HU HUE17863293A patent/HUE052087T2/hu unknown
- 2017-11-03 MX MX2019005256A patent/MX2019005256A/es unknown
- 2017-11-03 RU RU2019112589A patent/RU2757665C2/ru active
- 2017-11-03 DK DK17863293.1T patent/DK3407709T3/da active
- 2017-11-03 PL PL20180508.2T patent/PL3766343T3/pl unknown
- 2017-11-03 RS RS20220669A patent/RS63390B1/sr unknown
- 2017-11-03 EP EP20180508.2A patent/EP3766343B1/en active Active
- 2017-11-03 ES ES20180508T patent/ES2915609T3/es active Active
- 2017-11-03 CA CA3038720A patent/CA3038720A1/en active Pending
- 2017-11-03 PL PL17863293T patent/PL3407709T3/pl unknown
- 2017-11-03 KR KR1020217034468A patent/KR102492433B1/ko active IP Right Grant
- 2017-11-03 US US15/803,513 patent/US10820582B2/en active Active
- 2017-11-03 HR HRP20220888TT patent/HRP20220888T1/hr unknown
- 2017-11-03 ES ES17863293T patent/ES2823305T3/es active Active
- 2017-11-03 IL IL266282A patent/IL266282B2/en unknown
- 2017-11-03 CN CN202210050898.8A patent/CN114369157A/zh active Pending
- 2017-11-03 KR KR1020247012338A patent/KR20240055863A/ko active Search and Examination
- 2017-11-03 SI SI201730381T patent/SI3407709T1/sl unknown
- 2017-11-03 RU RU2021129958A patent/RU2021129958A/ru unknown
- 2017-11-03 MA MA053935A patent/MA53935A/fr unknown
-
2019
- 2019-05-03 MX MX2021010556A patent/MX2021010556A/es unknown
-
2020
- 2020-09-03 HR HRP20201403TT patent/HRP20201403T1/hr unknown
- 2020-09-24 US US17/031,367 patent/US20210029978A1/en active Pending
- 2020-10-29 CY CY20201101022T patent/CY1123491T1/el unknown
-
2021
- 2021-03-08 JP JP2021036180A patent/JP2021090455A/ja not_active Withdrawn
-
2022
- 2022-07-07 JP JP2022109658A patent/JP7386292B2/ja active Active
-
2023
- 2023-02-17 JP JP2023023312A patent/JP2023053400A/ja active Pending
-
2024
- 2024-01-31 AU AU2024200582A patent/AU2024200582A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903344XA (en) | Non-human animals having an engineered immunoglobulin lambda light chain locus | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201407370QA (en) | Humanized il-7 rodents | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201407789RA (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201806176PA (en) | Non-human animals having an engineered angptl8 gene |